Loading...
Loading...
CINGW| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 2,948.2K |
| Gross Profit | -2,948.2K |
| Operating Expense | 2,948.2K |
| Operating I/L | -5,896.4K |
| Other Income/Expense | -24.3K |
| Interest Income | 0.0K |
| Pretax | -2,972.5K |
| Income Tax Expense | -163.6K |
| Net Income/Loss | -2,972.5K |
Cingulate Inc. is a clinical-stage biopharmaceutical company specializing in the development of product candidates for central nervous system and neurobiological disorders. The company's lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), target attention deficit/hyperactivity disorders, while it also focuses on developing CTx-2103 for anxiety disorders. By advancing these product candidates through clinical trials and seeking regulatory approvals, Cingulate Inc. aims to generate revenue through the commercialization of its pharmaceutical products for the treatment of these disorders.
